Oculis Holding Ag's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Oculis Holding Ag (OCS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Oculis Holding Ag vs Its Competitors
- TTM: Trailing 12-month revenue of 1M vs 129,839M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+382.8% annualized vs trailing 12 months), vs accelerating (+133.9%) for its tracked peer group.
- Growth: Oculis Holding Ag generated 85.7% revenue growth year over year in Q4 2025, vs 9.3% for its tracked competitors combined.
- Profitability: Its -8,253.3% net margin compares with 20.5% for the peer group.
- Scale: Oculis Holding Ag ranks #196 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Oculis Holding Ag accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.02M compares with $0.93M for the peer group (0.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
OCS Sales vs. its Competitors, Q4 2025
Oculis Holding Ag reported revenue growth of 85.72 % year on year in Q4 2025, above its competitors' combined revenue growth of 9.29 %.
With a net margin of -8,253.30 %, Oculis Holding Ag reported lower profitability than its competitors (20.54 %).
Oculis Holding Ag generated 0.00 % of the combined sales of its peer group, up from 0.00 % a year earlier.
Oculis Holding Ag vs. its Competitors, Q4 2025
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Oculis Holding Ag and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Oculis Holding Ag | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Oculis Holding Ag's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 9.0% year over year, combined, vs 85.7% for Oculis Holding Ag. Oculis Holding Ag's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Oculis Holding Ag's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Oculis Holding Ag | - | Yes | Yes | No |
| Competitors combined (26) | ||||
| High-Confidence Competitors (9) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
OCS Stock Performance relative to its Competitors
OCS Stock Performance relative to High-Confidence Competitors
OCS Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Prelude Therapeutics Inc | 282.9% | Outperformed |
| 2 | Atea Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Bristol myers Squibb Company | 282.9% | Outperformed |
| 4 | Regeneron Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Novartis Ag | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Oculis Holding Ag's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Oculis Holding Ag's Comment on Competition and Industry Peers
Publicly Traded Peers of Oculis Holding Ag
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Oculis Holding Ag | 487.95 | 1.20 |
| Beone Medicines Ltd | 550,872.13 | 6,128.24 |
| Novartis Ag | 278,724.35 | 56,674.00 |
| Bristol myers Squibb Company | 127,795.20 | 49,186.00 |
| Regeneron Pharmaceuticals Inc | 80,376.62 | 15,534.70 |
| Legend Biotech Corporation | 7,332.27 | 1,028.90 |
| SUBTOTAL | 1,063,291.99 | 130,063.15 |
Sign in to see all competitors of Oculis Holding Ag.
Sources: Oculis Holding Ag's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Oculis Holding Ag versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Oculis Holding Ag's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Accure Therapeutics SL | Named by the company | 85% |
| Harrow | Named by the company | 85% |
| Teva Pharmaceuticals | Named by the company | 85% |
| High Tide inc | Named by the company | 85% |
| Bausch + Lomb | Named by the company | 85% |
| Roche | Named by the company | 85% |
| Alcon | Named by the company | 85% |
| Novartis | Named by the company | 85% |
| Viatris | Named by the company | 85% |
| Abbvie | Named by the company | 85% |
| Bayer | Named by the company | 85% |
| Sun Pharmaceuticals | Named by the company | 85% |
| ANI Pharmaceuticals | Named by the company | 85% |
| Regeneron | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Oculis Holding Ag's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Oculis Holding Ag's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Ocular Therapeutix Inc | Single Reportable Segment 100.00 % |
| Harrow Inc | Branded 79.40 % |
| Alimera Sciences Inc | United States Segment 67.09 % |
| Journey Medical Corp | Dermatological segment 100.00 % |
| Hyperion Defi inc | Digital Assets 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Oculis Holding Ag's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Oculis Holding Ag | 488 | 19,983 | -1,990,795 |
| Beone Medicines Ltd | 550,872 | 510,686 | 54,642 |
| Novartis Ag | 278,724 | 752,973 | 185,566 |
| Bristol myers Squibb Company | 127,795 | 1,513,415 | 285,354 |
| Regeneron Pharmaceuticals Inc | 80,377 | 1,008,092 | 280,902 |
| Legend Biotech Corporation | 7,332 | 354,793 | -102,345 |
| PEERS TOTAL | 1,062,804 | 926,506 | 190,906 |
Oculis Holding Ag's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Beone Medicines Ltd | United States 51.69 % |
| Bristol myers Squibb Company | United States 67.79 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Oculis Holding Ag's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Oculis Holding Ag's industry classification, broader than the peer set above. Market cap in millions of $.Oculis Holding Ag ranks #196 of 498 companies by market capitalization in its industry, holding 0.01 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,060,478 | 19.39 % |
| 2 | Johnson and Johnson | 652,141 | 11.92 % |
| 3 | Beone Medicines Ltd | 560,341 | 10.24 % |
| 4 | Abbvie Inc | 468,722 | 8.57 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 196 | Oculis Holding Ag | 477 | 0.01 % |
Market cap and industry share for the rest of Oculis Holding Ag's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-30.
Oculis Holding Ag's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 191 | Sagimet Biosciences inc | 509 | 38.44 % |
| 192 | Kamada Ltd | 501 | 24.89 % |
| 193 | Arvinas Inc | 491 | -12.43 % |
| 194 | Nuvectis Pharma inc | 481 | 246.45 % |
| 195 | Contineum Therapeutics Inc | 1,234 | 12.3% |
| 196 | Oculis Holding Ag | 477 | -48.00 % |
| 197 | Maplight Therapeutics Inc | 1,234 | 12.3% |
| 198 | Benitec Biopharma Inc | 1,234 | 12.3% |
| 199 | Prothena Corporation Public Limited Company | 1,234 | 12.3% |
| 200 | Vtv Therapeutics Inc | 1,234 | 12.3% |
| 201 | Diamedica Therapeutics Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Oculis Holding Ag's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-30. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Oculis Holding Ag's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 0.00 % | 64.64 % (avg) | -64.6 pp |
| Operating Margin | - | industry median | - |
| EBITDA Margin | - | -7.39 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 30.30 % | 4.93 % (avg) | +25.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Oculis Holding Ag's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | -3.18 % | -22.31 % | 74.78 % |
| Operating Margin | - | - | - |
| Return on Invested Capital | -44.01 % | -47.08 % | -23.43 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Oculis Holding Ag's BCG Growth-Share Matrix
Relative market share (vs Oculis Holding Ag's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Oculis Holding Ag falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Oculis Holding Ag's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 30.30 % vs industry average 4.93 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Oculis Holding Ag's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Oculis Holding Ag's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Oculis Holding Ag's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Oculis Holding Ag falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Oculis Holding Ag's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+382.8% annualized vs trailing 12 months).
Weaknesses
- Return on equity 76.7 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
No rule matched.
Threats
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Oculis Holding Ag's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Oculis Holding Ag | 2.21 | 5.96 | - |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Bristol myers Squibb Company | 0.49 | 1.35 | 2.31 |
| Regeneron Pharmaceuticals Inc | 0.57 | 3.74 | 0.06 |
| Legend Biotech Corporation | 1.42 | 1.96 | 0.01 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Oculis Holding Ag's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Oculis Holding Ag | Q4 2025 | +74.8 % | - |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Bristol myers Squibb Company | Q2 2026 | +5.7 % | +152.6 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +16.7 % | -6.8 % |
| Legend Biotech Corporation | Q4 2025 | +64.0 % | - |
| PEERS TOTAL | +10.5 % | +28.1 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Oculis Holding Ag's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Oculis Holding Ag | Q4 2025 | - | +39.1 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Bristol myers Squibb Company | Q2 2026 | +10.5 % | -15.5 % |
| Regeneron Pharmaceuticals Inc | Q2 2026 | +109.2 % | +9.7 % |
| Legend Biotech Corporation | Q4 2025 | +83.5 % | +102.8 % |
Oculis Holding Ag's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Oculis Holding Ag | - | - | - |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Bristol myers Squibb Company | 10.27% | 13.58% | 46.65% |
| Regeneron Pharmaceuticals Inc | 10.60% | 11.83% | 13.81% |
| Legend Biotech Corporation | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Oculis Holding Ag's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Oculis Holding Ag | - | 406.96 |
| Beone Medicines Ltd | 831.68 | 89.89 |
| Novartis Ag | 19.93 | 4.92 |
| Bristol myers Squibb Company | 13.74 | 2.60 |
| Regeneron Pharmaceuticals Inc | 18.78 | 5.17 |
| Legend Biotech Corporation | - | 7.13 |
| PEERS AVERAGE | 39.85 | 8.18 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.